Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2024 11:15 ET | Source: Imbria Pharmaceuticals Inc.

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...
November 14, 2023 13:00 ET | Source: DelveInsight Business Research LLP

Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis

New York, USA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics,...
June 22, 2023 09:54 ET | Source: Growth Plus Reports

Hypertrophic Cardiomyopathy Market to Hit US$ 1.35 Billion by 2031| Exclusive Report by Growth Plus Reports

Newark, New Castle, USA, June 22, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market for hypertrophic cardiomyopathy in 2022 to be worth US$ 1.12 billion, and it is...
May 17, 2023 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
December 05, 2022 08:00 ET | Source: Imbria Pharmaceuticals Inc.

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
April 02, 2020 11:50 ET | Source: Reports and Data

Hypertrophic Cardiomyopathy Therapeutics Market To Reach USD 1.42 Billion By 2027 | Reports and Data

New York, April 02, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Hypertrophic Cardiomyopathy Therapeutics Market valued at USD 1.20 Billion in 2019 and...
November 04, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA)...
November 08, 2011 11:00 ET | Source: American Heart Association

Most Americans With HCM Live Normal Life Spans

Statement Highlights: Hypertrophic cardiomyopathy (HCM) is a treatable disease compatible with normal longevity. HCM is the most common inherited cardiac disease, occurring in one per 500...